ANANDA Scientific Announces a Clinical Trial Evaluating Nantheia™ ATL5, in the treatment of Co-Occurring Opioid Use Disorder and Chronic Pain
ANANDA Scientific Inc., a research-focused biopharmaceutical company, today announced the commencement of a clinical trial evaluating Nantheia™ ATL5, an investigational drug using cannabidiol (CBD), leveraging ANANDA’s proprietary delivery technology, co-administered with delta-9-tetrahydrocannabinol (THC), for its potential efficacy in treating co-occurring opioid use disorder (OUD) and chronic pain. (Clinical Trials.gov Identifier: NCT06544291)
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241015941899/en/
(Photo: Business Wire)
The trial will be conducted at the Yale School of Medicine. The study will be led by Principal Investigator Joao P. De Aquino, M.D., Director of the Pain and Addiction Interaction Neurosciences (PAIN) Laboratory, and Assistant Chief of Inpatient Psychiatry at Yale School of Medicine. Funding for this trial is through a grant from the National Institute on Drug Abuse (NIDA).
The primary objective of this trial is to investigate the therapeutic potential of Nantheia™ ATL5, co-administered with THC, in relieving both pain and cue-induced craving in people with OUD and chronic pain. The secondary objective is to determine if adding a THC dose independently alters the effect of Nantheia™ ATL5 (CBD) alone.
This will be a randomized, double blind, placebo controlled, cross over study with participants who are maintained on stable doses of methadone randomly assigned to receive single doses of Nantheia™ ATL5 (CBD 200mg, 400mg or placebo), with THC (5mg, 10mg or placebo).
“We are excited to collaborate with ANANDA to get this trial underway,” said Dr. De Aquino. “Understanding how CBD, co-administered with low doses of THC, may work together to benefit patients with OUD and chronic pain could lead to significant advancements in treating these debilitating conditions.”
“We are delighted to be working with Dr. De Aquino and Yale School of Medicine on this important trial for our investigational drug Nantheia™ ATL5,” said Sohail R. Zaidi, ANANDA’s Chief Executive Officer. “This clinical trial is a further important step in our clinical development efforts focused on opioid addiction, where a non-addictive therapy is a significant unmet medical need.”
ABOUT NANTHEIA™ ATL5
Nantheia™ ATL5 is an investigational drug that combines cannabidiol with ANANDA’s proprietary Liquid Structure™ delivery technology. Pre-clinical and initial clinical studies show that ANANDA’s Liquid Structure™ delivery technology (licensed from Lyotropic Delivery Systems (LDS) Ltd in Jerusalem, Israel) enhances the effectiveness, consistent absorption and stability of cannabidiol. Nantheia™ ATL5 is an oral product with 100 mg of cannabidiol per softgel capsule.
About ANANDA Scientific
ANANDA Scientific is a leading research-focused biopharmaceutical company focused on developing life changing medicines to transform neuropsychiatric health. The company is currently conducting high-caliber clinical studies evaluating therapeutic indications such as PTSD, Pain, Anxiety, Opioid Use Disorder and Smoking Cessation. The company’s patented delivery technology makes cannabinoids and plant-derived compounds highly bioavailable, water-soluble, and shelf-life stable. ANANDA Scientific is dedicated to producing effective, premium pharmaceutical products that enhance patients’ lives.
This press release includes forward-looking statements that involve risks and uncertainties. Such statements are based on current assumptions and expectations, which may change over time.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241015941899/en/
Contacts
For more information, please contact:
ANANDA Scientific Inc.
Chris Moore
chris.moore@anandascientific.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Citi and Ant International Pilot AI-Enabled Forecasting Solution to Enhance FX Risk Management for Airline Customers18.7.2025 05:30:00 EEST | Press release
Citi and Ant International announced today that they are piloting the use of Ant International's Falcon Time-Series Transformer (TST) Model to deliver an enhanced FX risk management solution for their customers. Developed with aviation clients as an initial use case, the solution aims to offer greater payment solutions for the airline industry, which processes billions of payment transactions annually. With airline travel set to continue growing, the joint solution combines Ant International's experience with airline payments and Citi's robust FX solutions to help the bank's clients manage their FX costs more efficiently. Ant International’s Falcon TST Model is a transformer architecture-based big data model with close to 2 billion parameters. By integrating the latest time series forecasting algorithms, the TST Model predicts future data points by learning complex patterns from large historical data sets using AI technology, the model helps businesses improve the efficiency and accura
AGC Launches Innovative Fluoroelastomer Without the Use of Surfactants or Fluorinated Polymerization Solvents18.7.2025 05:00:00 EEST | Press release
AGC (AGC Inc., Headquarters: Tokyo; President: Yoshinori Hirai)(TOKYO:5201), a world-leading manufacturer of glass, chemicals and other high-tech materials, proudly announces the launch of surfactant and fluorinated polymerization solvent free grades in its fluoroelastomer “AFLAS™ FFKM” series; the SF grades (the “Products”). The newly developed Products are manufactured entirely without the use of any surfactants*1 or fluorinated polymerization solvents*2. The Products offer high performance equivalent to that of conventional products, while meeting the growing market demand for fluoroelastomers that do not use surfactants or fluorinated polymerization solvents during the manufacturing process. This has been achieved through AGC’s innovative, proprietary polymer manufacturing technology (Surfactant-Free & Fluoro Solvent-Free Technology, hereafter the “Technology”). Initially, this Technology will be applied to the high-temperature-resistant type of FFKM fluoroelastomers and new grades
Dubai Launches World’s First Icon Classification for Human–Machine Collaboration in Research and Publications17.7.2025 19:40:00 EEST | Press release
Dubai has launched the world’s first icon-based classification system to represent the level of human–machine collaboration in the process of producing research, publications, and public-facing content. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250717193317/en/ Dubai launches world’s first icon classification for Human–Machine Collaboration in research and publications (Infographic: AETOSWire) Developed by the Dubai Future Foundation (DFF), the Human–Machine Collaboration (HMC) Icons offer a new global standard for transparency, clearly indicating the extent to which humans and AI worked together throughout the creation process. The classification is free to use, copyrighted for consistency, and openly available for researchers, publishers, and content creators worldwide. His Highness Sheikh Hamdan bin Mohammed bin Rashid Al Maktoum, Crown Prince of Dubai, Deputy Prime Minister, Minister of Defence, and Chairman of the
Battery Ventures Promotes Justin Rosner to Partner17.7.2025 16:47:00 EEST | Press release
Battery Ventures, a global, technology-focused investment firm, today announced nearly a dozen new internal promotions across four offices, including the elevation of Justin Rosner—a specialist in industrial technology and life-science tools—to partner. Battery also named four new principals across its venture-capital and private-equity practices, highlighting the firm’s penchant for promoting talent from within the firm. The new principals are Sudheendra Chilappagari in San Francisco; Michael Hoeksema in New York; Lior Mallul in Tel Aviv; and Lauren Wedell in Boston. Wedell and Mallul both joined Battery in 2018, while Hoeksema joined in 2017. Chilappagari, a former founder and technology product executive, joined the firm in 2021. “These promotions highlight Battery’s continued, global investment focus, even in the face of macroeconomic uncertainty, and our commitment to backing the most innovative companies across the private-equity and venture-capital markets,” said Jesse Feldman,
Andersen Consulting Adds Market Access Expertise with Prime Action in Brazil17.7.2025 16:30:00 EEST | Press release
Andersen Consulting strengthens its capabilities in Latin America with the addition of collaborating firm Prime Action Consulting, a firm specializing in market access strategy and channel management within the automotive, agribusiness, banking, pharmaceutical, and telecommunications sectors. Prime Action delivers end-to-end commercial consulting services to help organizations optimize their go-to-market strategies and improve performance across sales and distribution channels. The firm’s offerings include market access strategy, intelligent channel management, commercial and distribution policy design, channel development services, and training, all tailored to drive efficiency and customer alignment through structured processes, standards, and targeted execution. Working with top-tier companies across Latin America, Prime Action not only works in lockstep with clients from planning through implementation, but also post-implementation to provide appropriate training and evaluation to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom